Migraine Treatment with Botulinum Toxin

Individual cost plan after consultation

Chronic migraine — at least 15 headache days a month — with botulinum toxin type A following the approved PREEMPT protocol: 31 injection points across seven muscle groups, every twelve weeks. In the pivotal trials with 1,384 treated patients, headache days fell by 8.4 per month, versus 6.6 under placebo. Assessment after two cycles, no treatment without an endpoint. Below the approval threshold, on a case-by-case basis off-label, after counseling. Specialist in Anesthesiology, low-pain injection technique.

Headache · Chronic Migraine · Approved Prophylaxis

For chronic migraine — at least 15 headache days a month — botulinum toxin type A following the PREEMPT protocol is an approved, guideline-consistent preventive treatment. In the pivotal trials, headache days fell by 8.4 per month; under placebo, by 6.6. The difference is real and well established. It doesn't mean freedom from symptoms — and I say that before the first injection.

Cycle12 weeksRepeated at a fixed interval. Assessment no earlier than after two cycles.
Protocol31 pointsSeven muscle groups, 155–195 units, following PREEMPT. About 20 minutes.
Effect−8.4 daysHeadache days per month after 24 weeks; placebo −6.6. Pooled data from 1,384 treated patients.

Common reasons patients come in

Does this sound familiar?

"More days with headache than without"

Cancelled appointments, days in a darkened room, the dread of the next attack. Anyone with headache on more than half of all days no longer has "severe migraine" — they have a chronic condition, and with it, a different treatment option.

"Three preventive tablets, all discontinued"

Topiramate, beta-blockers, amitriptyline — ineffective, or with side effects that weren't tolerable in daily life. That's exactly the prerequisite for the approval. In the FORWARD study, 51% of those treated with topiramate discontinued due to side effects, versus 4% under botulinum toxin.

"I thought it was tension headache"

Many patients classify their own headache this way — and, on structured questioning, meet all the criteria for chronic migraine, often with an additional tension component. These mixed pictures stay under-treated under the wrong diagnosis.

In short

Botulinum toxin type A has been approved in Germany since 2011 for the prevention of chronic migraine — for adults with at least 15 headache days a month over more than three months, at least 8 of them with migraine features, who have not responded adequately to oral preventive treatment. The basis is the PREEMPT study program: two randomized, double-blind, placebo-controlled trials with 1,384 participants. Treatment follows a fixed protocol with 31 injection points across seven muscle groups in the head, neck and shoulders, every twelve weeks. For episodic migraine and for pure tension-type headache, the treatment is not approved and is not recommended in the German guideline. Below this threshold I still treat on a case-by-case basis — off-label, after separate counseling and with a clear statement that the evidence there is thinner. It does not replace acute therapy.

Safety profile

What you can realistically expect

A note on terminology: Many patients search for “Botox” — a brand name of one single product that has become a colloquial umbrella term. The active substance is botulinum toxin type A, contained in several licensed medicinal products. All of them are prescription-only and are injected exclusively by the physician after a medical examination. This page uses the substance name throughout — it refers to the same treatment commonly known as a Botox treatment.

The process

Why this practice

31 injections are a question of technique.

The most common question before the first appointment isn't about the effect — it's about the 31 injections. Very fine needles, superficial injections, about 15 minutes. In anesthesiology, low-pain injection is daily routine — injection angle, speed, sequence, skin tension. Across 31 points, these details add up.

As a Specialist in Anesthesiology with an additional qualification in emergency medicine, I bring two things that matter here: routine with anatomical structures and injection techniques — and the ability to recognize and manage rare complications where they occur. I am a certified member of the DGBT (German Society for Aesthetic Botulinum Toxin Therapy). Where accompanying tension is present, I add Manual Medicine (additional qualification).

Botulinum toxin following PREEMPT is rarely offered in practices: it requires full implementation of all 31 points, a fixed interval, and the willingness to see patients through several cycles. That's why patients come to Herzogenaurach from Nuremberg, Fürth, Forchheim, Höchstadt and Bamberg.

How your appointment unfolds

  1. Initial consultation and history per ICHD-3. Headache diary, migraine days, prior preventive treatments and how well they were tolerated, painkiller use (to rule out overuse), accompanying muscle tension. Classification: approved indication or off-label case-by-case decision — both are stated openly. Counseling per Section 630e of the German Civil Code (BGB). Please disclose blood-thinning medication beforehand — and never discontinue it on your own. The initial consultation can be scheduled on the same day as the first cycle if the classification is clear.
  2. Treatment following the PREEMPT protocol. 31 points across seven muscle groups: corrugator and procerus muscles (glabella), frontalis muscle, temporalis muscle, occipitalis muscle, neck muscles, upper trapezius — 155 units fixed, up to 195 depending on pain distribution. About 15–25 minutes. No restriction on driving afterward.
  3. Onset of effect. After 1–4 weeks, gradually. What's typical isn't the absence of migraine, but rarer, shorter or milder attacks. In the first days, a sensation of pressure at the forehead or neck can occur, which resolves on its own.
  4. Second cycle after 12 weeks. Appointments on a fixed rhythm, plannable long-term. Headache diary as the measurement basis.
  5. Assessment after two cycles (24 weeks). Relevant improvement → continuation, supported long-term over 2 years (COMPEL, REPOSE). No improvement → discontinuation and a conversation about alternatives, such as CGRP antibodies.

The next step

Findings first. Then the decision.

Whether the indication fits, which prior therapies make sense, what expectation is realistic — that belongs in a personal conversation. Private practice in Herzogenaurach, on average 15 minutes by car from Erlangen (depending on your starting point), thirty from Nuremberg and Fürth. Parking directly at the practice.

Dr. med. Thomas Ackermann

Treating physician

Dr. med. Thomas Ackermann

Specialist in Anesthesiology · Medical director, HZO Ästhetik · Med

The approval is narrowly defined: at least 15 headache days a month over three months. Anyone meeting it gets the figures from the studies, not a promise. Anyone below that threshold who still suffers gets an honest assessment — and, if it fits after counseling, an off-label trial with a clear endpoint.

CV and career →

Read on

For everyone who wants to know more

Side effects in detail
Observation Frequency Duration
Neck pain, muscle weakness in the treated area common (1–10%) days to weeks, temporary
Pain or bruising at injection sites common (1–10%) days
Sensation of pressure at the forehead or neck in the first days common resolves on its own
Calmer expression at forehead and temple regular — a side effect of the forehead points, not a goal for as long as the effect lasts
Drooping eyelid, dry eyes, swallowing difficulty uncommon (0.1–1%) weeks
Insufficient response about one third respond little or not at all treatment is ended after two cycles, not continued indefinitely
Allergic reaction, systemic effects rare —

Adverse events per PREEMPT (Dodick 2010) and the prescribing information. They are generally temporary, since the effect fades after 3–4 months. Further detail in the safety overview.

What migraine treatment with botulinum toxin is not

Important to know

What migraine treatment with botulinum toxin is not

  • Not an acute therapy. It prevents; it does not treat an ongoing attack. Triptans and pain medication remain — in a medically supervised amount.
  • Not a cure-all. About half achieve a halving of headache days; about a third show little or no effect. Anyone expecting freedom from symptoms will be disappointed; anyone expecting fewer, milder days has the realistic expectation.
  • Not a standard below the approval threshold. Episodic migraine and tension-type headache are off-label: no approval, no guideline recommendation, thinner evidence. Where I treat there, it is a case-by-case decision after counseling — not a promised outcome and not a substitute for neurological workup.
  • Not a treatment without an endpoint. Assessment happens after two cycles (24 weeks). Without relevant improvement, it is ended, not continued. Where it works, long-term treatment is possible; after some years, longer intervals or pauses can be tried.
The approval is narrowly defined
Headache pattern Features Botulinum toxin
Chronic migraine (ICHD-3) ≥15 headache days/month over >3 months, at least ≥8 with migraine features; inadequate response to at least three oral preventive treatments (e.g. topiramate, beta-blockers, amitriptyline, flunarizine) or intolerance Approved — the indication for this page
Migraine with a tension component ≥8 clear migraine days plus further days with pressing, bilateral headache — meets the criteria for chronic migraine Approved as migraine therapy; often clinically under-treated because it gets classified as "tension headache"
Episodic migraine <15 headache days/month Not approved (off-label); evidence base considerably thinner; not recommended in the guideline. In this practice, a case-by-case decision, generally from around eight burdensome headache days a month — after separate counseling
Pure tension-type headache Pressing, bilateral, without migraine features Not approved (off-label); case-by-case decision at several days a month, often a mixed picture with migraine — see Tension Headache
Medication-overuse headache Painkillers on >10–15 days/month First, medication withdrawal under medical supervision, then reassess

Criteria per ICHD-3 (International Headache Society) and the guideline "Therapy of Migraine Attacks and Prophylaxis of Migraine" (DGN/DMKG, AWMF 030-057). Anyone with apparently treatment-resistant "tension headaches" should be reassessed per ICHD-3 — the correct diagnosis often opens the door to the correct therapy.

Why I also treat below the approval threshold

The approval and the guideline describe what has been proven effective in large trials: chronic migraine from 15 days upward. For fewer days and for tension-type headache, this proof is missing — that doesn't mean it doesn't work, only that it hasn't been studied in this form. What speaks in favor of treatment in individual cases: the substance's side-effect profile is well known from decades of use and is low in the head-and-neck region, the effect wears off on its own after three to four months, and the trial is concluded after one or two cycles — measured against a headache diary, not a feeling. Anyone who chooses this does so as an off-label application after separate counseling and without a promised outcome. In the least favorable case, what remains is a smoother forehead.

What PREEMPT showed — and what it didn't
Endpoint Botulinum toxin Placebo
Headache days per month, change after 24 weeks −8.4 −6.6 (p < 0.001)
Migraine days, days with severe headache, headache hours, impact (HIT-6) All significant in favor of botulinum toxin — exception: number of acute-medication intakes, no difference
Halving of headache days (≥50%) after 12 weeks, FORWARD study 45.6% 29.4% under topiramate (comparison against oral prevention, not against placebo)
Adverse events overall 62.4% 51.7%
Discontinuation due to adverse events 3.8% 1.2%

Pooled data from the two PREEMPT trials (Dodick et al. 2010, PMID 20487038; 1,384 adults, 155–195 units every 12 weeks) and FORWARD (Rothrock et al. 2019, PMID 31559634). Important context: the placebo group also improved markedly — a study effect, expectation, regression to the mean. The additional effect of botulinum toxin was around 1.8 fewer days per month. That sounds modest, but is clinically relevant for chronically burdened patients. The long-term data from COMPEL (108 weeks, 716 treated patients) and REPOSE (a European real-world study over 2 years) confirm efficacy and safety with continued treatment.

My clinical approach

The guideline draws the line at 15 headache days a month. Suffering doesn't follow that number: eight days are still eight lost days, and four can shape a family's life. That's why the classification comes first — approved indication or off-label case-by-case decision — not the treatment protocol. I discuss both openly: with the figures from the studies where they exist, and with the sentence "this isn't proven" where they don't.

— Dr. med. Thomas Ackermann · Specialist in Anesthesiology

The studies in detail
  • Dodick DW, Turkel CC, DeGryse RE et al., 2010. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50(6):921–936. PMID 20487038. Pooled analysis of both pivotal trials, 1,384 adults, 155–195 units every 12 weeks: headache days −8.4 versus −6.6 under placebo after 24 weeks (p < 0.001), all secondary endpoints significant except acute medication use. Adverse events 62.4% vs 51.7%, discontinuations 3.8% vs 1.2%.
  • Aurora SK, Dodick DW, Turkel CC et al., 2010. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793–803. PMID 20647170. The first of the two pivotal trials.
  • Diener HC, Dodick DW, Aurora SK et al., 2010. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804–814. PMID 20647171. The second pivotal trial, primary endpoint headache days.
  • Rothrock JF, Adams AM, Lipton RB et al., 2019. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. Headache 59(10):1700–1713. PMID 31559634. 282 randomized adults, open-label comparison with topiramate: halving of headache days in 40% vs 12% (accounting for discontinuations), observed at 12 weeks 45.6% vs 29.4%. Discontinuation due to side effects 4% vs 51%.
  • Blumenfeld AM, Stark RJ, Freeman MC et al., 2018. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 19(1):13. PMID 29404713. Open-label long-term study over nine treatments across 108 weeks: sustained reduction in headache days, no new safety signals.
  • Davies B, Gaul C, Martelletti P et al., 2017. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. J Headache Pain 18(1):93. PMID 28879545. Prospective European real-world study over 24 months in seven countries including Germany, 644 enrolled patients.
  • Frampton JE, Silberstein S, 2018. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs 78(5):589–600. PMID 29532439. Review of approval, efficacy and safety.
  • Frampton JE, 2020. OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use. CNS Drugs 34(12):1287–1298. PMID 33314008. Summary of PREEMPT, COMPEL, REPOSE and FORWARD: sustained, clinically meaningful improvement over 1–2 years.

Study data researched via PubMed. Guideline: DGN/DMKG, "Therapy of Migraine Attacks and Prophylaxis of Migraine," AWMF 030-057; classification: ICHD-3 (International Headache Society). The pivotal trials were funded by the manufacturer. The results cited are averages across patient groups — the individual effect is not predictable.

Frequently asked questions

About migraine treatment with botulinum toxin

How quickly will I notice an effect?

Gradually. Initial effects often appear after 1–2 weeks, full effect after 4–6 weeks. Success is assessed no earlier than after 12 weeks — one complete cycle — and reliably after two cycles. That's also what the guideline recommends.

How many sessions do I need?

At least two cycles, 12 weeks apart, for the assessment of success. Where it works, long-term continuation is possible — COMPEL demonstrated safety and efficacy over 108 weeks in 716 treated patients, and REPOSE over two years in European practices. Some patients can try longer intervals or pauses after some years.

What can I realistically expect?

In the pivotal trials, 8.4 fewer headache days per month versus 6.6 under placebo. In the FORWARD study, 45.6% achieved a halving of headache days after 12 weeks. About a third respond little or not at all. What I see in consultations I'm not permitted to report as anecdotal evidence — the study figures are the more honest basis.

Is the effect visible in the face?

The protocol includes points at the forehead and temple; there, the expression can appear calmer. The dosing is designed for headache prevention, not for smoothing lines; a frozen expression does not result from correct application. If you specifically don't want that effect, the distribution can be adjusted within the protocol.

Does health insurance cover the cost?

For chronic migraine meeting the approval criteria, it is a recognized indication. This practice bills according to the German fee schedule for physicians (GOÄ). Private health insurers generally reimburse when the indication is met, depending on the tariff. Patients with statutory health insurance can receive the treatment as a self-pay service; reimbursement under Section 13 of the German Social Code Book V (SGB V) is possible in individual cases, but unusual. For off-label treatment below the approval criteria, reimbursement is generally not to be expected. I discuss the cost framework before the decision — see the overview under Costs.

What about CGRP antibodies?

Erenumab, galcanezumab and fremanezumab have been approved for migraine prevention since 2018 — including for the episodic form. They work through a different mechanism and are injected under the skin monthly or quarterly. Both therapies are effective; the choice depends on prior treatments, tolerability, reimbursement and preference. A topic for the personal conversation — and for neurology.

Could medication overuse be my problem?

Anyone taking pain medication on more than 10–15 days a month can develop medication-overuse headache — a common reason for apparently treatment-resistant chronic headache. This needs to be clarified before botulinum toxin treatment. The first step is then a medically supervised withdrawal from pain medication over several weeks.

Does the treatment hurt?

31 very fine, superficial injections, each comparable to a brief pinprick. The session takes about 15 minutes. Most patients find it well tolerated; you can drive yourself home directly afterward.

Is my migraine connected to jaw clenching?

Possibly. Bruxism, tension headache and migraine share biological pathways and often occur together. Where the chewing muscle is tender to pressure, it's worth looking at the whole pattern: Teeth Grinding · Tension Headache.

Related content

Further reading

  • Tension HeadacheWhen botulinum toxin helps, when it doesn't — the distinction from migraine.
  • Teeth GrindingWhen migraine comes together with jaw clenching.
  • Manual MedicineA complement where there is a muscular component in the neck and shoulder girdle.
  • Forehead LinesWhy the forehead points of the protocol make the expression appear calmer — and what that has to do with the line of convergence.
  • PREEMPT in DetailThe full evidence base, the treatment cascade per the DGN guideline, and the distinction from episodic migraine.
  • Safety and Side EffectsOverview of all possible reactions, with frequency, duration and management.
  • Aftercare GuidanceThe 24-hour and 14-day routine.

Notice per Section 630e of the German Civil Code (BGB). This patient information serves general education and does not replace the personal counseling conversation. Establishing the indication, counseling on efficacy, risks, side effects and alternatives, and consent all take place exclusively at the personal appointment. Treatment with botulinum toxin type A for chronic migraine is approved under German drug law; use follows the prescribing information and the applicable guidelines. Use outside the approval (off-label) — for example for episodic migraine or tension-type headache — takes place only after separate counseling on the more limited evidence. For medical emergencies, contact 112 or the non-emergency medical on-call service (116 117). What to keep in mind after your treatment is covered on the aftercare page for botulinum toxin type A.

This page gives a first overview. What a treatment means specifically for you — which method, which dose, what to realistically expect — belongs in a personal conversation at the practice. Unhurried, with a proper assessment, with time.

Dr. med. Thomas Ackermann | HZO Ästhetik · Med · Niederndorfer Hauptstraße 41 · 91074 Herzogenaurach · Phone 09132 90 24 770